BNP and NT-proBNP levels are elevated in various critical illnesses and pulmonary diseases, serving as potential markers of severity and prognosis beyond heart failure.
What is the clinical utility of BNP and NT-proBNP in critical illness and pulmonary diseases?
BNP and NT-proBNP are not specific to heart failure and can be elevated in various critical illnesses and pulmonary diseases, where they may indicate disease severity and prognosis.
OBJECTIVE: B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), although promising as biomarkers for heart failure, are affected by multiple confounders. The purpose of this article is to review the literature on the utility of BNP and NT-proBNP as biomarkers, with a focus on their role in critical illness and pulmonary diseases. DATA SOURCE: Published articles on BNP and NT-proBNP. DATA ANALYSIS: Multiple disorders in the intensive care unit cause elevated BNP and NT-proBNP levels, including cardiac diseases, shock, pulmonary hypertension, acute respiratory distress syndrome, acute pulmonary embolism, chronic obstructive pulmonary disease, renal failure, and other conditions. CONCLUSIONS: Intensivists and pulmonologists should understand that BNP and NT-proBNP levels might be raised to different degrees not only in heart failure but also in critical illness and various pulmonary diseases; in these situations, BNP and NT-proBNP may also serve as markers of severity and prognosis.
Phua et al. (Thu,) conducted a review in Critical illness and pulmonary diseases. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) was evaluated on Utility as biomarkers of severity and prognosis. BNP and NT-proBNP levels are elevated in various critical illnesses and pulmonary diseases, serving as potential markers of severity and prognosis beyond heart failure.